Patent Yard Sign in
Expired Canadian patentCanada

Compositions and methods of using lamellar bodies for therapeutic purposes

CA 2540328 C · Owner: Dobbie, James · Inventors: Dobbie, James

CIPO record

Overview

Drawings and full text

Its claims, description and drawings are in the Canadian Patents Database.

Open the CIPO record

Abstract From the Canadian patent

Compositions comprising therapeutically effective amounts of lamellar bodies for the modification of linear macromolecules are disclosed. These lamellar compositions are useful in the treatment of conditions or diseases characterized by a preponderance of heavy mucous secretions such as otitis , media, cystic fibrosis bronchitis, sinusitis and nasal congestion. Methods of treating these diseases and conditions by administering a therapeutically effective amount of a composition to a patient requiring such treatment are also disclosed.

Read the whole patent

Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.

Why it's free to use

  • Filed August 31, 2004 and granted November 20, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended August 31, 2024.
  • A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 31, 2026.
  • We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
FiledAugust 31, 2004
GrantedNovember 20, 2012
Term endedAugust 31, 2024
Patent numberCA 2540328 C
Classification (IPC)A61K31/68 +2 more

Timeline

Timeline From CIPO dates

2005200720092011201320152017201920212023Application filedAug 31, 2004Patent grantedNov 20, 2012Term endedAug 31, 2024

Sources & verification

Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.